This comprehensive review by O’Kane et al. explores the evolving landscape of liver machine perfusion, highlighting promising advancements and remaining challenges. Since Guarrera et al. published the first ex-situ HMP clinical series in 2010, HMP has been found to decrease ischemia reperfusion injury, early allograft dysfunction rates, and ischemic cholangiopathy.
LifePort Liver Transporter is not currently commercially available; pending FDA approval.
The authors detail more recent literature involving both HOPE and D-HOPE techniques that found additional benefits to grafts from extended-criteria DBDs and DCDs, such as improved graft-survival, reduction in post-op complications, and shorter hospital stays. Notably in Europe, researchers utilize HMP to reduce IRI and subsequently NMP for viability assessment. They also discussed utilizing machine perfusion after NRP.
Read the full article here: https://link.springer.com/article/10.1007/s40137-024-00434-8
The Latest
